MAP2K7 and RASopathy: Considering multisystem manifestations of the underlying RASopathy in our child, including aggressive orbital rhabdomyosarcoma that was resistant to radiochemotherapy and required radical mutilating surgery, we chose MEK-inhibitor treatment with trametinib to modulate the general molecular pathogenetic mechanism from the HRAS genetic mosaicism.